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Abstract
Endofeed® DC is a preparation of endo-1,3(4)-b-glucanase and endo-1,4-b-xylanase to be used as a
feed additive for chickens for fattening, laying hens, pigs for fattening and minor poultry and porcine
species. In a previous assessment, the safety of the additive for the target species, user and environment
as well as the efﬁcacy were established. In that assessment, the applicant provided in order to address
the safety for the consumer, a bacterial reverse mutation assay and an in vitro micronucleus test, and
a subchronic oral toxicity study. However, considering the limitations on the description of the
manufacturing process, the characterisation of the additive and on the toxicological studies provided, the
Panel could not conclude on the safety for the consumer. The applicant provided new data/information
on the manufacturing process, characterisation of the additive and new toxicological studies, to support
the safety for the consumer, which was the main subject of this opinion. Complete and detailed
information regarding the manufacturing process of the additive, including details on the composition of
the intermediate products were provided. With the new information on the manufacturing and on the
test items used in the toxicological studies evaluated in 2013, the Panel identiﬁed the need for new
genotoxicity studies, while conﬁrmed the appropriateness of the test item used in the subchronic oral
toxicity study. New genotoxicity studies were submitted by the applicant and the results of the tests
showed no genotoxic potential of the test items. The Panel considered that the conclusions drawn in the
subchronic oral toxicity study previously submitted can be considered valid; the results showed no
evidence for adverse effects. Therefore, the Panel concluded that the additive is safe for the consumers
when used as a feed additive.
© 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
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Summary
Following a request from the European Commission, the Panel on Additives and Products or
Substances used in Animal Feed (FEEDAP) was asked to deliver a scientiﬁc opinion on the safety of
Endofeed® DC (endo-1,3(4)-b-glucanase and endo-1,4-b-xylanase) as a feed additive for chickens for
fattening, laying hens, pigs for fattening and minor poultry and porcine species.
In 2013, the FEEDAP Panel adopted an opinion on the safety and efﬁcacy of Endofeed® DC as a
feed additive for chickens for fattening, laying hens, pigs for fattening and minor poultry and porcine
species. The safety of the additive for the target species, user and environment and the efﬁcacy were
established at that time. In the previous assessment, the applicant provided in order to address the
safety for the consumer a bacterial reverse mutation assay and an in vitro micronucleus test, and a
subchronic oral toxicity study. However, considering the limitations on the description of the
manufacturing process, the characterisation of the additive and on the toxicological studies provided
the Panel could not conclude on the safety for the consumer. The applicant has now provided new
data/information on the manufacturing process, characterisation of the additive and toxicological
studies to assess the safety for the consumer, which are the main subject of this opinion.
In the current assessment, the applicant provided complete and detailed information regarding the
manufacturing process of the additive, including details on the composition of the intermediate
products. Moreover, the applicant provided supplementary information regarding the composition of
the additive, the absence of the production strain, the content of mycotoxins as well as secondary
metabolites of the production strain.
With the newly provided information on the manufacturing and on the test items used in the
toxicological studies evaluated in 2013, the Panel identiﬁed the need for new genotoxicity studies while
conﬁrmed the appropriateness of the test item used in the subchronic oral toxicity study. New
genotoxicity studies were submitted by the applicant. Due to the characteristics of the manufacturing
process, the applicant prepared extracts of the fermentation product: water and dimethylsulfoxide
extracts were prepared in order to ensure the recovery of any product present in the fermentation
product. The two extracts obtained were tested separately in the bacterial reverse mutation test and
also in the in vitro mammalian cell micronucleus test. The results of the tests showed no genotoxic
potential of the test items. The Panel considered that the conclusions drawn in the subchronic oral
toxicity study previously submitted can be considered valid; the results showed no evidence for
adverse effects.
The results obtained in the genotoxicity studies and in the subchronic oral toxicity study did not
indicate any reason for concern for consumer safety arising from the use of the product as a feed
additive. Therefore, the Panel concluded that the additive is safe for the consumers when used as a
feed additive.
Endofeed® DC for poultry and pigs for fattening
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Regulation (EC) No 1831/2003 establishes rules governing the Community authorisation of additives
for use in animal nutrition and in particular, Article 9 thereof deﬁnes the terms of such authorisation by
the Commission.
The applicant Andres Pintaluba S.A. is seeking an authorisation of its endo-1,3(4)-b-glucanase and
endo-1,4-b-xylanase to be used as zootechnical additive (Table 1).
On 11 July 2013, the Panel on Additives and Products or Substances used in Animal Feed of the
Authority, in its opinion on the safety and efﬁcacy of the product, could not conclude on the consumer
safety based on the lack of adequate studies provided by the applicant.
The Commission gave the possibility to the applicant to submit complementary information in order
to complete the safety assessment and allow a revision of the Authority’s opinion.
The data generated by the applicant and compiled in the above-mentioned supplementary
information have been sent directly to the Authority by the applicant.
In view of the above, the Commission asks the Authority to deliver an updated opinion on the
safety of endo-1,3(4)-b-glucanase and endo-1,4-b-xylanase as zootechnical additive, based on the
additional data submitted by the applicant.
1.2. Additional information
Endofeed® DC is an enzyme preparation that contains endo-1,3(4)-b-glucanase and endo-1,4-b-
xylanase. EFSA issued an opinion on the use of Endofeed® DC as a zootechnical additive (functional
group: digestibility enhancers) for chickens for fattening, laying hens, pigs for fattening and minor
poultry and porcine species (EFSA FEEDAP Panel, 2013). However, the manufacturing process was not
fully described and the Panel could not conclude on the safety of the additive for the consumers.
2. Data and methodologies
2.1. Data
The present assessment is based on data submitted by the applicant in the form of supplementary
information1 to a previous application on the same product.2
2.2. Methodologies
The approach followed by the FEEDAP Panel to assess the safety of Endofeed® DC is in line with
the principles laid down in Regulation (EC) No 429/20083 and the relevant guidance documents:
Guidance on zootechnical additives (EFSA FEEDAP Panel, 2012a), Technical guidance: Tolerance and
efﬁcacy studies in target animals (EFSA FEEDAP Panel, 2011), Technical Guidance: Microbial Studies
(EFSA, 2008), and Guidance for establishing the safety of additives for the consumer (EFSA FEEDAP
Panel, 2012b).
Table 1: Description of the substances
Category of additive Zootechnical additives
Functional group of additive Digestibility enhancers
Description Endo-1,3(4)-b-glucanase and endo-1,4-b-xylanase
Target animal category Chickens for fattening, laying hens, pigs for fattening and minor
poultry and porcine species
Applicant Andres Pintaluba S.A.
Type of request Update opinion
1 FEED dossier reference: FAD-2014-0018.
2 FEED dossier reference: FAD-2009-0015.
3 Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC)
No 1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications
and the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.
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3. Assessment
Endofeed® DC is an enzyme preparation which contains per gram, a minimum of 1,100 Units of
endo-1,3(4)-b-glucanase (glucanase) and 1,600 Units of endo-1,4-b-xylanase (xylanase) that is
intended to be used as a zootechnical additive (functional group: digestibility enhancers) for chickens
for fattening, laying hens, pigs for fattening and minor poultry and porcine species. The enzymes are
produced by Aspergillus niger NRRL 25541.
In the assessment performed in 2013 (EFSA FEEDAP Panel, 2013), the safety of this additive for
the target species, user and environment and the efﬁcacy were established. However, considering the
limitations on the description of the manufacturing process, the characterisation of the additive and on
the toxicological studies provided, the Panel could not conclude on the safety for the consumer. The
applicant has now provided new data/information on the manufacturing process, characterisation of
the additive and toxicological studies to assess the safety for the consumer, which is the main subject
of this opinion.
3.1. Characterisation4
In the previous assessment (EFSA FEEDAP Panel, 2013), the information regarding the
manufacturing missed relevant information for the fermentation steps and the characteristics of the
resulting products, including the presence of the production strain.
The applicant submitted in the current assessment detailed information on the manufacturing
process: including explanations of the different fermentation steps, on the resulting products
(composition) and on the methodologies followed to kill the production strain. This information allowed
the Panel to fully characterise the manufacturing and the composition of the additive itself.
The applicant accompanied the information on the manufacturing with data on the batch-to-batch
variation in the enzyme activity, the absence of the production strain and purity data.
The batch-to-batch variation in ﬁve batches showed compliance with the minimum speciﬁcations
(mean value of 1,388 glucanase U/g product (1,188–1,534 U/g) and 2,000 U xylanase/g (1,680–
2,314 U/g)).5 The presence of the production strain in the ﬁnal product was evaluated in the same
batches of the additive and was not found (limit of detection 5 colony forming units (CFU)/g).6
The raw material used to prepare the additive (four batches), the ﬁnal additive (ﬁve batches) and a
water extract of the additive (one batch) were analysed for the presence of mycotoxins in a
multimycotoxin screening test.7 The mycotoxins investigated were found to be below the limit of
quantiﬁcation.8,9 One batch of the additive was analysed for secondary metabolites that can be
produced by A. niger including malformin C (0.3 mg/kg), oxalic acid (26 g/kg), nigragillin (0.2 mg/kg),
aurasperone (not detected, limit of detection < 500 lg/kg) and nigerazines (not detected, limit of
detection < 100 lg/kg).10
New studies looking for the presence of antimicrobial activity were provided: the freeze-dried water
extract of the additive (used in the genotoxicity studies, see below) showed no antimicrobial activity
against ﬁve bacterial strains recommended by EFSA (EFSA, 2008b).11 The applicant declared that no
antimicrobial substances are used in the manufacturing process.12
4 This section has been amended following the conﬁdentiality claims made by the applicant.
5 Technical dossier FAD-2014-0018/Annex II.3.4.
6 Health Canada Method for the microbiological analysis of foods, yeast and moulds, method MFHPB-22.
7 Technical dossier FAD-2014-0018/Supplementary information July 2015/Annexes II.1.4.3, II.1.4.4 and II.1.4.5.
8 The mycotoxins investigated in the substrate and ﬁnal product were: aﬂatoxins B1 (< 5 µg/kg), B2 (< 3 µg/kg), G1
(< 7 µg/kg) and G2 (< 9 µg/kg), deoxynivalenol (< 100 µg/kg), fumonisin B1 (< 40 µg/kg), B2 (< 100 µg/kg) and B3
(< 80 µg/kg), HT-2 toxin (< 80 µg/kg), ochratoxin A (< 8 µg/kg), sterigmatocystin (< 4 µg/kg), T-2 toxin (< 90 µg/kg) and
zearalenone (< 70 µg/kg).
9 The mycotoxins investigated in the water extract were: aﬂatoxins B1 (< 0.5 µg/kg), B2 (< 0.3 µg/kg), G1 (< 0.7 µg/kg) and
G2 (< 0.9 µg/kg), deoxynivalenol (< 10 µg/kg), fumonisin B1 (< 4 µg/kg), B2 (< 10 µg/kg) and B3 (< 8 µg/kg), HT-2 toxin
(< 8 µg/kg), ochratoxin A (< 0.8 µg/kg), sterigmatocystin (< 0.4 µg/kg), T-2 toxin (< 9 µg/kg), zearalenone (< 7 µg/kg),
diacetoxyscirpenol (< 10 µg/kg), acetyldeoxinivalenol (< 13 µg/kg), ergocristine (< 5 µg/kg), ergocryptine (< 6 µg/kg),
ergosine (< 9 µg/kg), neosolaniol (< 10 µg/kg), nivalenol (< 7 µg/kg), a-zearalenol (< 5 µg/kg) and b-zearalenol (< 7 µg/kg).
10 Technical dossier/Supplementary information November 2016/Annex II.1.4.7.
11 Technical dossier FAD-2014-0018/Annex II.1.4.6.
12 Technical dossier FAD-2014-0018/Supplementary information November 2016.
Endofeed® DC for poultry and pigs for fattening
www.efsa.europa.eu/efsajournal 6 EFSA Journal 2017;15(3):4706
3.2. Safety for the consumer13
In the previous assessment (EFSA FEEDAP Panel 2013), the applicant provided a bacterial reverse
mutation assay and an in vitro micronucleus test, and a subchronic oral toxicity study. However, the
Panel could not conclude on the suitability of the studies, due to the characteristics of the test items
used, its relationship with the additive under assessment and methodologies followed.
With the information provided in the current assessment on the manufacturing and on the test
items used in the studies evaluated in 2013, the Panel identiﬁed the need for new genotoxicity studies
while conﬁrmed the appropriateness of the test item used in the subchronic oral toxicity studies (see
below). The applicant has provided new genotoxicity studies.
3.2.1. Genotoxicity studies
Owing to the characteristics of the manufacturing process and its resulting products, the applicant
was requested to use extracts of the fermentation product. To ensure the complete extraction of
possible by-products from the fermentation product, water and dimethylsulfoxide (DMSO) extracts
were prepared. Aliquots of the fermentation product were separately suspended in water or in DMSO,
overnight under continuous stirring. The samples obtained after separation of cells and particles, were
concentrated by freeze-drying, in the case of the water extract or by vacuum evaporation at 50°C, in
the case of the DMSO extract.
3.2.1.1. Bacterial reverse mutation tests
The two extracts were tested separately in Salmonella Typhimurium strains TA1535, TA1537, TA98,
TA100, TA102 following the OECD Guideline 471.14 The freeze-dried water extract was diluted in
distilled water and tested up to a concentration of 5,000 lg/plate. The DMSO extract was diluted in
DMSO and the maximum concentrations tested were 40 lg/plate or mL, due to a considerable
precipitation that hindered the scoring, although no cytotoxicity was reported. For each extract, two
independent experiments were conducted, with and without metabolic activation (S9 mix from rat
livers induced by Aroclor 1254). The second assay was performed according to the pre-incubation
method with metabolic activation and according to the plate incorporation without metabolic
activation. With the DMSO extract and owing to a dosage error in the second experiment, a third
experiment only with metabolic activation (pre-incubation method) was conducted.
With the water extract, neither cytotoxicity nor precipitation is observed. No increase in the number
of revertants over the threshold of biological signiﬁcance (twofold) and/or over historical control was
observed in any experimental condition, while the positive controls produced the expected mutagenic
effect.
With the DMSO extract in the third experiment, a 2.5 times increase in the number of revertants
was noted at the highest dose of 30 lL/mL in strain TA98. This increase was not conﬁrmed in a fourth
experiment performed under the same experimental conditions. No other increase in the number of
revertants was observed. The positive controls performed as expected.
3.2.1.2. In vitro micronucleus test
The two extracts were tested separately in the in vitro mammalian cell micronucleus test on TK6
lymphoblastoid human cells, following the OECD Guideline 487.15 The freeze-dried water extract was
diluted in distilled water and a top concentration of 2,000 lg/mL was selected on the basis of a
preliminary cytotoxicity test. The DMSO extract was diluted in DMSO and the test concentrations were
deﬁned as percentages; the top concentration was 0.5%, based on a preliminary cytotoxicity test. The
following treatment schedules were used: 3 h’ treatment followed by 24 h’ recovery time, with and
without metabolic activation (S9 mix from rat livers induced by Aroclor 1254); 27 h continuous
treatment without recovery time, only without metabolic activation. Two independent cultures were
used and 1,000 cells per culture per concentration were scored.
The two extracts did not induce any statistically signiﬁcant increase in the number of
micronucleated cells at any of the concentrations analysed, while the positive controls were clearly
effective, showing the sensitivity of the test system.
13 This section has been amended following the conﬁdentiality claims made by the applicant.
14 Technical dossier FAD-2014-0018/Supplementary information July 2015/Annex III.2.2.5 and III.2.2.7.
15 Technical dossier FAD-2014-0018/Supplementary information July 2015/Annexes III.2.2.6 and III.2.2.8.
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3.2.2. Subchronic oral toxicity study
In the previous assessment, the applicant provided a subchronic oral toxicity study in rats (EFSA
FEEDAP Panel, 2013). In that study, the rats were fed the additive instead of the fermentation product
used to formulate the additive as recommended by the Guidance for establishing the safety of
additives for the consumer (EFSA FEEDAP Panel, 2012b). The supplementary information submitted in
the current assessment allows the Panel to conclude that in this case the use of the additive is valid.
In particular, considering the manufacturing process, resulting product and the highest treatment
concentration (12.5 g/kg feed) the actual treatment dosage can be considered sufﬁcient. The results
showed that there is no evidence for adverse effects.
3.2.3. Conclusions on the safety for the consumer
The results obtained in the genotoxicity studies and in the subchronic oral toxicity study do not
indicate any reason for concern for consumer safety arising from the use of the product as a feed
additive.
3.3. Post-market monitoring
The FEEDAP Panel considers that there is no need for speciﬁc requirements for a post-market
monitoring plan other than those established in the Feed Hygiene Regulation16 and Good
Manufacturing Practice.
4. Conclusion
The use of Endofeed® DC as a feed additive does not give rise to safety concerns for consumers.
Documentation provided to EFSA
1) Supplementary information Endofeed® DC. April 2014. Submitted by Andres Pintaluba S.A.
2) Supplementary information Endofeed® DC. Supplementary information. July 2015. Submitted
by Andres Pintaluba S.A.
3) Supplementary information Endofeed® DC. Supplementary information. November 2016.
Submitted by Andres Pintaluba S.A.
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